サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1479066

幹細胞アッセイの世界市場の評価：アッセイタイプ別、細胞タイプ別、製品タイプ別、用途タイプ別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Stem Cell Assays Market Assessment, By Assay Type, By Cell Type, By Product Type, By Application Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日
ページ情報
英文 223 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
幹細胞アッセイの世界市場の評価：アッセイタイプ別、細胞タイプ別、製品タイプ別、用途タイプ別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
出版日: 2024年05月14日
発行: Market Xcel - Markets and Data
ページ情報: 英文 223 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の幹細胞アッセイの市場規模は、2023年の15億4,000万米ドルから2031年に48億米ドルに達すると予測され、2024年～2031年の予測期間にCAGRで15.27%の成長が見込まれます。市場は近年著しい成長を示しており、今後も堅調な拡大ペースを維持すると予測されます。幹細胞アッセイとは、幹細胞の特性や作用を評価するための実験手法です。幹細胞の自己複製能、さまざまな細胞種への分化能、増殖能を評価するために、管理された条件下で幹細胞を試験します。幹細胞アッセイは、生物医学研究や再生医療において重要であり、創薬や薬剤開発から毒性学的スクリーニングや疾患モデリングまで、幅広い応用が可能です。さらに幹細胞アッセイは、治療薬となりうる薬剤が幹細胞の分化や機能性に及ぼす影響を調べることで、医薬品開発において重要な役割を果たしています。さらに、これらのアッセイは、発生過程の研究、薬理学的毒性のスクリーニング、がんや神経疾患などの疾患の根本的な原因究明にも利用されています。

幹細胞研究の絶え間ない進歩と、幹細胞の単離・培養・分化に向けた革新的な技術の登場が主な促進要因となっています。このような技術の進歩は、幹細胞アッセイの効率と有効性を高め、創薬や再生医療、基礎研究などのさまざまな用途において幹細胞アッセイをますます魅力的なものにしています。3次元細胞培養法、ハイスループットスクリーニング手法、イメージングや分析器具の進歩などの革新が、総体として市場拡大に寄与しています。

循環器疾患、神経疾患、糖尿病といったさまざまな疾患に対する幹細胞の可能性とともに、再生医療への関心の急速な高まりが、幹細胞アッセイに対する需要を後押ししています。さらに、慢性疾患や遺伝性疾患の世界的な増加により、新規の治療薬や治療法の開発が必要とされています。幹細胞はそのような治療法を生み出す有望な手段となるため、疾患モデリング、医薬品開発、個別化医療における幹細胞アッセイの需要が促進されています。学術界や製薬企業が疾病の病因に関する理解を深め、新たな治療法を評価する取り組みを強化するにつれて、幹細胞アッセイの必要性は高まり続けています。政府、企業、学術機関は、治療への応用を模索するために幹細胞研究への投資を増やしており、幹細胞を用いた治療法の有効性と安全性を評価するアッセイに対する需要を生み出しています。例えば、FUJIFILM Cellular Dynamicsは2022年3月にPromega Corporationと提携し、ヒトの細胞生物学を最終的に理解するためのシステムで細胞生物学がどのように機能するかを理解するための新規アッセイを開発しました。

疾病の有病率の上昇

がん、心血管系疾患、糖尿病、神経疾患などの慢性疾患や生活習慣病の有病率の増加は、幹細胞アッセイ市場拡大の重要なカタリストとなっています。豚インフルエンザやエボラ出血熱などの感染症の急増も、治療薬や医薬品開発部門の成長に拍車をかけています。例えば、2021年12月27日～2022年1月9日、WHO Global Influenza Surveillance and Response System（GISRS）の検査室は、99ヶ国の検査室から31万7,198件以上の検体を分析しました。これらの検査のうち、1万6,862人がインフルエンザウイルス陽性と判定され、その63.7％がA型インフルエンザ、36.3％がB型インフルエンザでした。疾患の流行とその反復性は、これらの疾患の理解と対策における幹細胞アッセイの重要性を明示しています。さらに、老年人口や小児人口が増加するにつれて、疾病の罹患率も増加し、幹細胞検査に対する需要をさらに押し上げています。2022年7月現在、国連の予測によると、世界の小児人口（0～17歳）は23億人で、2040年に25億人に達すると予測されています。小児人口の継続的な増加は、革新的なソリューションに対するニーズの高まりを意味し、幹細胞アッセイ市場は今後数年間に持続的な成長を示すと予測されます。

当レポートでは、世界の幹細胞アッセイ市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の幹細胞アッセイ市場の見通し（2017年～2031年）

  • 市場規模と予測
    • 金額
    • 数量
  • アッセイタイプ別
    • 生存率/細胞毒性アッセイ
    • 分離・精製アッセイ
    • 細胞同定アッセイ
    • 増殖アッセイ
    • 分化アッセイ
    • 機能アッセイ
    • アポトーシスアッセイ
  • 細胞タイプ別
    • 成体幹細胞
    • ヒト胚性幹細胞
  • 製品タイプ
    • 器具
    • 試薬、キット
  • 用途タイプ別
    • 再生医療・治療法開発
    • 創薬・医薬品開発
    • 臨床研究
  • エンドユーザー別
    • バイオ医薬品、バイオテクノロジー企業
    • 学術機関、研究施設
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南アメリカエンドユーザー
    • 中東・アフリカ
  • 市場シェア：企業別（2023年）

第5章 世界の幹細胞アッセイ市場の見通し：地域別（2017年～2031年）

  • 北米
    • 市場規模と予測
    • アッセイタイプ別
    • 細胞タイプ別
    • 製品タイプ
    • 用途タイプ別
    • エンドユーザー別
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • ロシア
    • オランダ
    • スペイン
    • トルコ
    • ポーランド
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • オーストラリア
    • ベトナム
    • 韓国
    • インドネシア
    • フィリピン
  • 南米
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ

第6章 市場マッピング（2023年）

  • アッセイタイプ別
  • 細胞タイプ別
  • 製品タイプ
  • 用途タイプ別
  • エンドユーザー別
  • 地域別

第7章 マクロ環境と産業構造

  • 需給分析
  • 輸入輸出分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第8章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第9章 規制枠組みとイノベーション

  • 臨床試験
  • イノベーション/新技術

第10章 主要企業の情勢

  • マーケットリーダー上位5社の競合マトリクス
  • マーケットリーダー上位5社の市場収益分析（2023年）
  • 合併と買収/合弁事業（該当する場合）
  • SWOT分析（市場企業5社）
  • 特許分析（該当する場合）

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

  • GE Healthcare Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Merck & Co., Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Promega Corporation
  • Cell Biolabs, Inc.
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Fujifilm Holdings Corporation

第14章 戦略的推奨

第15章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 3.Global Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 4.Global Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 5.Global Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 6.Global Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 7.Global Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 8.Global Stem Cell Assays Market Share (%), By Region, 2017-2031F
  • Figure 9.North America Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 10.North America Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 11.North America Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 12.North America Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 13.North America Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 14.North America Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 15.North America Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 16.North America Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 17.United States Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 18.United States Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 19.United States Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 20.United States Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 21.United States Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 22.United States Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 23.United States Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 24.Canada Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 25.Canada Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 26.Canada Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 27.Canada Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 28.Canada Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 29.Canada Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 30.Canada Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 31.Mexico Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 32.Mexico Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 33.Mexico Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 34.Mexico Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 35.Mexico Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 36.Mexico Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 37.Mexico Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 38.Europe Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 39.Europe Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 40.Europe Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 41.Europe Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 42.Europe Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 43.Europe Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 44.Europe Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 45.Europe Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 46.Germany Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.Germany Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 48.Germany Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 49.Germany Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 50.Germany Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 51.Germany Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 52.Germany Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 53.France Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 54.France Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 55.France Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 56.France Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 57.France Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 58.France Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 59.France Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 60.Italy Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 61.Italy Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 62.Italy Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 63.Italy Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 64.Italy Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 65.Italy Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 66.Italy Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 67.United Kingdom Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 68.United Kingdom Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 69.United Kingdom Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 70.United Kingdom Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 71.United Kingdom Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 72.United Kingdom Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 73.United Kingdom Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 74.Russia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 75.Russia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 76.Russia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 77.Russia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 78.Russia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 79.Russia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 80.Russia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 81.Netherlands Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 82.Netherlands Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 83.Netherlands Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 84.Netherlands Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 85.Netherlands Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 86.Netherlands Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 87.Netherlands Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 88.Spain Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Spain Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 90.Spain Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 91.Spain Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 92.Spain Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 93.Spain Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 94.Spain Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 95.Turkey Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 96.Turkey Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 97.Turkey Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 98.Turkey Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 99.Turkey Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 100.Turkey Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 101.Turkey Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 102.Poland Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 103.Poland Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 104.Poland Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 105.Poland Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 106.Poland Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 107.Poland Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 108.Poland Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 109.South America Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 110.South America Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 111.South America Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 112.South America Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 113.South America Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 114.South America Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 115.South America Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 116.South America Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 117.Brazil Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 118.Brazil Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 119.Brazil Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 120.Brazil Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 121.Brazil Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 122.Brazil Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 123.Brazil Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 124.Argentina Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 125.Argentina Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 126.Argentina Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 127.Argentina Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 128.Argentina Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 129.Argentina Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 130.Argentina Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 131.Asia-Pacific Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 132.Asia-Pacific Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 133.Asia-Pacific Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 134.Asia-Pacific Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 135.Asia-Pacific Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 136.Asia-Pacific Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 137.Asia- Pacific Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 138.Asia-Pacific Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 139.India Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 140.India Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 141.India Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 142.India Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 143.India Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 144.India Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 145.India Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 146.China Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 147.China Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 148.China Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 149.China Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 150.China Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 151.China Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 152.China Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 153.Japan Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 154.Japan Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 155.Japan Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 156.Japan Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 157.Japan Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 158.Japan Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 159.Japan Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 160.Australia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 161.Australia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 162.Australia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 163.Australia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 164.Australia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 165.Australia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 166.Australia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 167.Vietnam Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 168.Vietnam Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 169.Vietnam Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 170.Vietnam Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 171.Vietnam Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 172.Vietnam Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 173.Vietnam Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 174.South Korea Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 175.South Korea Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 176.South Korea Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 177.South Korea Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 178.South Korea Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 179.South Korea Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 180.South Korea Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 181.Indonesia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.Indonesia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 183.Indonesia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 184.Indonesia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 185.Indonesia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 186.Indonesia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 187.Indonesia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 188.Philippines Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 189.Philippines Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 190.Philippines Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 191.Philippines Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 192.Philippines Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 193.Philippines Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 194.Philippines Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 195.Middle East & Africa Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 196.Middle East & Africa Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 197.Middle East & Africa Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 198.Middle East & Africa Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 199.Middle East & Africa Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 200.Middle East & Africa Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 201.Middle East & Africa Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 202.Middle East & Africa Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 203.Saudi Arabia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 204.Saudi Arabia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 205.Saudi Arabia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 206.Saudi Arabia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 207.Saudi Arabia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 208.Saudi Arabia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 209.Saudi Arabia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 210.UAE Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 211.UAE Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 212.UAE Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 213.UAE Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 214.UAE Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 215.UAE Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 216.UAE Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 217.South Africa Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 218.South Africa Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 219.South Africa Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 220.South Africa Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 221.South Africa Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 222.South Africa Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 223.South Africa Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 224.By Assay Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225.By Cell Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226.By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227.By Application Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX11317

Global stem cell assays market is projected to witness a CAGR of 15.27% during the forecast period 2024-2031, growing from USD 1.54 billion in 2023 to USD 4.8 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years. A stem cell assay is a laboratory method used to evaluate the characteristics and actions of stem cells. It involves testing stem cells under controlled conditions to assess their capacity for self-renewal, differentiation into various cell types, and proliferation. Stem cell assays are important in biomedical research and regenerative medicine, offering applications ranging from drug discovery and development to toxicological screening and disease modeling. Moreover, stem cell assays play a crucial role in drug development by examining the effects of potential therapeutic drugs on stem cell differentiation and functionality. Additionally, these assays are employed to study developmental processes, screen for pharmacological toxicities, and investigate the underlying causes of diseases such as cancer and neurological disorders.

Constant progress in stem cell research, coupled with the emergence of innovative techniques for stem cell isolation, cultivation, and differentiation, serve as primary drivers. These technological advancements enhance the efficiency and efficacy of stem cell assays, rendering them increasingly attractive for various applications, including drug development, regenerative medicine, and fundamental research. Innovations such as 3D cell culture methodologies, high-throughput screening approaches, and advancements in imaging and analytical instruments collectively contribute to market expansion.

The burgeoning interest in regenerative medicine, alongside the potential of stem cells to address various ailments such as cardiovascular disease, neurological disorders, and diabetes, fuels the demand for stem cell assays. Moreover, the rising global prevalence of chronic diseases and genetic disorders necessitates the development of novel therapeutics and treatments. Stem cells offer a promising avenue for generating such therapies, consequently driving the demand for stem cell assays in disease modeling, drug development, and personalized medicine. As academia and pharmaceutical companies intensify efforts to deepen their understanding of disease etiology and evaluate new treatments, the necessity for stem cell assays continues to grow. Governments, corporations, and academic institutions are increasingly investing in stem cell research to explore therapeutic applications, thereby generating demand for assays to assess stem cell-based therapies' efficacy and safety. For instance, Fujifilm cellular dynamics collaborated with Promega Corporation in March 2022 to develop novel assays to understand how cellular biology works in a system to understand cell biology in humans ultimately.

Rising Prevalence of Diseases

The increasing prevalence of chronic diseases and lifestyle-related disorders, including cancer, cardiovascular conditions, diabetes, and neurological ailments, serves as a significant catalyst for the expansion of the stem cell assay market. The upsurge in infectious diseases, such as swine flu and Ebola, has also fueled growth in the therapeutics and drug development sector. For instance, between December 27, 2021, and January 9, 2022, WHO Global Influenza Surveillance and Response System (GISRS) laboratories analyzed over 317,198 specimens from labs across 99 countries. Among these tests, 16,862 individuals tested positive for influenza viruses, with 63.7% identified as influenza A and 36.3% as influenza B. The prevalence of diseases and their recurring nature underscore the importance of stem cell assays in understanding and combating these conditions. Moreover, the expanding geriatric and pediatric populations drive the increased incidence of diseases, further boosting the demand for stem cell assays. As of July 2022, United Nations Projections indicated a global pediatric population (0-17 years) of 2.3 billion, projected to reach 2.5 billion by 2040. The ongoing rise in the pediatric population signifies a growing need for innovative solutions, positioning the stem cell assays market for sustained growth in the coming years.

Growing Emphasis On Clinical Research & Development

The expansion of the global stem cell assays market is being propelled by factors such as clinical research and development. There is a strong emphasis on comprehending cancer biology and identifying innovative therapeutic targets for a wide range of acute and chronic diseases, significantly contributing to the growth of the stem cell assays market. Moreover, substantial investments in research and development endeavors by pharmaceutical companies and academic institutions are fostering market expansion. The escalating prevalence of chronic diseases such as cancer, osteoarthritis, cardiovascular diseases, and diabetes drives the demand for cell-based assays in the quest for novel drug discoveries, thereby serving as a pivotal growth factor for this market segment. According to an article titled "2022 Funding forecast: strong R&D growth with clouds on the horizon," published in April 2022, the United States federal government is projected to allocate USD 181.4 billion for research and development in 2022, further bolstering growth prospects for this segment.

Clinical trials play a pivotal role in assessing the safety and efficacy of new drugs, ultimately leading to regulatory approvals and market penetration. These trials validate the therapeutic potential of drugs and augment the empirical evidence supporting their clinical utility. Additionally, collaboration among commercial entities, academic institutions, and regulatory bodies expedites the clinical development process of various stem cell assays and accelerates the introduction of novel drugs to the market. In April 2023, Omisirge (omidubicel-onlv), a significantly modified allogeneic (donor) cord blood-based cell therapy was granted approval by US FDA.

Dominance of Reagent and Kits

During the projected period, the reagents and kits segment are expected to lead the stem cell assays market. These consumables play a vital role in various stem cell tests, encompassing cell proliferation, differentiation, viability, and toxicity assessments. Their pervasive use in routine laboratory operations and recurring necessity contribute to their high demand. This demand is fueled by ongoing research and development endeavors in both academic and commercial sectors, where stem cell assays are pivotal for drug discovery, therapeutic advancement, and fundamental research. Reagents and kits are formulated to address a broad spectrum of requirements, ranging from fundamental research to specialized therapeutic domains. This adaptability is reinforced by the capacity to customize kits for specific stem cell types or assays. Such tailored solutions and application versatility ensure sustained high demand for reagents and kits across diverse research domains and pharmaceutical development initiatives, consolidating their market dominance. Moreover, in contrast to instruments, which entail significant upfront capital investment and maintenance costs, reagents and kits are more cost-effective and accessible to a broader customer base, including small research laboratories and entrepreneurs. In March 2022, Illumina launched the TruSight Oncology (TSO) comprehensive in-vitro genomic profiling kit in Europe. The kit evaluates multiple genes and biomarkers to elucidate the precise molecular profile of cancer patients, empowering clinicians to administer tailored therapies based on individual molecular profiles.

North America Dominates Global Stem Cell Assays Market Share

North America dominates the global stem cell assays market, primarily due to its well-established healthcare sector and widespread adoption of cell-based assays. In the United States, the rising incidence of chronic diseases like cancer, osteoarthritis, and diabetes drives demand for cell-based assays, thus serving as a significant growth driver for this market.

For instance, according to data from the American Cancer Society's Cancer Facts & Figures 2022 report, an estimated 1.9 million new cancer cases will be diagnosed in the United States, along with 609,360 cancer-related deaths. Similarly, American Heart Association reported in January 2022 that a myocardial infarction occurs approximately every 40 seconds in the United States. Such high prevalence of chronic diseases in the population of the United States is expected to propel stem cell assays market growth during the forecast period.

Future Market Scenario (2024 - 2031F)

Occurrence and re-occurrence in number of acute and non-acute diseases call for a solution and it presents the biggest opportunity for the stem cell assays market to rise. Adoption of much advanced and effective approaches are being devised that should ensure faster recovery and better results for a better quality of life. R&D and heavy investments made by healthcare giants are promoting developments in the stem cell assays market, which is optimistic for the market to flourish in the coming years. New brands in this development area are introducing themselves with cutting edge technologies.

For instance, in February 2024, Thermo Fisher unveiled a novel serum-free stem cell culture medium designed to enhance stem cell proliferation and differentiation. The breakthrough holds significant promise for companies engaged in developing stem cell-based therapies. Successful attempts to improve diagnostics push the industry as a whole to engage further with higher-quality R&D, which paves the way for the market to rise. In August 2022, Life Net Health LifeSciences launched Cell-Based Assay Services, including cytotoxicity screening, biocompatibility assays, and others.

Key Players Landscape and Outlook

Several companies in global stem cell assays market are focusing on new product release, market expansion, and product development. Stem cell assays market players are poised to encounter promising growth prospects in the global market, driven by the increasing demand for diagnostic solutions. The primary focus of these leading players is directed towards the rapidly expanding market segment, aiming to thrive and excel in an intensely competitive market environment. Additionally, these market players emphasize collaboration and license agreements as strategic initiatives are anticipated to propel the market growth.

In July 2022, CORESTEM, based in South Korea, continued to enroll participants for the Phase 3 clinical trial of NeuroNata-R. The treatment has obtained conditional approval for the treatment of amyotrophic lateral sclerosis (ALS) patients in South Korea.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Stem Cell Assays Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Assay Type
    • 4.2.1.Viability/Cytotoxicity Assays
    • 4.2.2.Isolation & Purification Assays
    • 4.2.3.Cell Identification Assays
    • 4.2.4.Proliferation Assays
    • 4.2.5.Differentiation Assays
    • 4.2.6.Function Assays
    • 4.2.7.Apoptosis Assays
  • 4.3.By Cell Type
    • 4.3.1.Adult Stem Cells
    • 4.3.2.Human Embryonic Stem Cells
  • 4.4.By Product Type
    • 4.4.1.Instruments
    • 4.4.2.Reagents and Kits
  • 4.5.By Application Type
    • 4.5.1.Regenerative Medicine & Therapy Development
    • 4.5.2.Drug Discovery & Development
    • 4.5.3.Clinical Research
  • 4.6.By End-user
    • 4.6.1.Biopharmaceutical and Biotechnology Companies
    • 4.6.2.Academic Institutes and Research Facilities
    • 4.6.3.Others
  • 4.7.By Region
    • 4.7.1.North America
    • 4.7.2.Europe
    • 4.7.3.Asia-Pacific
    • 4.7.4.South End-user America
    • 4.7.5.Middle East and Africa
  • 4.8.By Company Market Share (%), 2023

5.Global Stem Cell Assays Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Assay Type
      • 5.1.2.1.Viability/Cytotoxicity Assays
      • 5.1.2.2.Isolation & Purification Assays
      • 5.1.2.3.Cell Identification Assays
      • 5.1.2.4.Proliferation Assays
      • 5.1.2.5.Differentiation Assays
      • 5.1.2.6.Function Assays
      • 5.1.2.7.Apoptosis Assays
    • 5.1.3.By Cell Type
      • 5.1.3.1.Adult Stem Cells
      • 5.1.3.2.Human Embryonic Stem Cells
    • 5.1.4.By Product Type
      • 5.1.4.1.Instruments
      • 5.1.4.2.Reagents and Kits
    • 5.1.5.By Application Type
      • 5.1.5.1.Regenerative Medicine & Therapy Development
      • 5.1.5.2.Drug Discovery & Development
      • 5.1.5.3.Clinical Research
    • 5.1.6.By End-user
      • 5.1.6.1.Biopharmaceutical and Biotechnology Companies
      • 5.1.6.2.Academic Institutes and Research Facilities
      • 5.1.6.3.Others
    • 5.1.7.United States*
      • 5.1.7.1.Market Size & Forecast
        • 5.1.7.1.1.By Value
        • 5.1.7.1.2.By Volume
      • 5.1.7.2.By Assay Type
        • 5.1.7.2.1.Viability/Cytotoxicity Assays
        • 5.1.7.2.2.Isolation & Purification Assays
        • 5.1.7.2.3.Cell Identification Assays
        • 5.1.7.2.4.Proliferation Assays
        • 5.1.7.2.5.Differentiation Assays
        • 5.1.7.2.6.Function Assays
        • 5.1.7.2.7.Apoptosis Assays
      • 5.1.7.3.By Cell Type
        • 5.1.7.3.1.Adult Stem Cells
        • 5.1.7.3.2.Human Embryonic Stem Cells
      • 5.1.7.4.By Product Type
        • 5.1.7.4.1.Instruments
        • 5.1.7.4.2.Kits and Reagents
      • 5.1.7.5.By Application Type
        • 5.1.7.5.1.Regenerative Medicine & Therapy Development
        • 5.1.7.5.2.Drug Discovery & Development
        • 5.1.7.5.3.Clinical Research
      • 5.1.7.6.By End-user
        • 5.1.7.6.1.Biopharmaceutical and Biotechnology Companies
        • 5.1.7.6.2.Academic Institutes and Research Facilities
        • 5.1.7.6.3.Others
    • 5.1.8.Canada
    • 5.1.9.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Assay Type
  • 6.2.By Cell Type
  • 6.3.By Product Type
  • 6.4.By Application Type
  • 6.5.By End-user
  • 6.6.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.GE Healthcare Technologies Inc.
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Thermo Fisher Scientific Inc.
  • 13.3.Merck & Co., Inc.
  • 13.4.Bio-Rad Laboratories, Inc.
  • 13.5.Bio-Techne Corporation
  • 13.6.Promega Corporation
  • 13.7.Cell Biolabs, Inc.
  • 13.8.Danaher Corporation
  • 13.9.Becton, Dickinson and Company
  • 13.10.Fujifilm Holdings Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer